Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Afatinib Therapy: Practical Management of Adverse Events With an Oral Agent for Non-Small Cell Lung Cancer Treatment.

Edwards RL, Andan C, Lalla RV, Lacouture ME, O'Brien D, Sequist LV.

Clin J Oncol Nurs. 2018 Oct 1;22(5):542-548. doi: 10.1188/18.CJON.542-548.

PMID:
30239509
2.

Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study.

Kang D, Kim IR, Choi EK, Im YH, Park YH, Ahn JS, Lee JE, Nam SJ, Lee HK, Park JH, Lee DY, Lacouture ME, Guallar E, Cho J.

Oncologist. 2018 Aug 17. pii: theoncologist.2018-0184. doi: 10.1634/theoncologist.2018-0184. [Epub ahead of print]

PMID:
30120165
3.

Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC.

Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD.

Cancer Immunol Res. 2018 Sep;6(9):1093-1099. doi: 10.1158/2326-6066.CIR-17-0755. Epub 2018 Jul 10.

PMID:
29991499
4.

Li-Fraumeni Syndrome-related Malignancies Involving the Genitourinary Tract: Review of a Single-institution Experience.

Murray KS, Spaliviero M, Tonorezos ES, Lacouture ME, Tap WD, Oeffinger KC, Vargas HA, Eastham JA.

Urology. 2018 Sep;119:55-61. doi: 10.1016/j.urology.2018.06.008. Epub 2018 Jun 21.

PMID:
29935265
5.

Pruritus Associated with Targeted Anticancer Therapies and Their Management.

Wu J, Lacouture ME.

Dermatol Clin. 2018 Jul;36(3):315-324. doi: 10.1016/j.det.2018.02.010. Review.

PMID:
29929603
6.

CME Part 2: Hair disorders in cancer survivors Persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, and hair growth disorders related to endocrine therapy or cancer surgery.

Freites-Martinez A, Shapiro J, van den Hurk C, Goldfarb S, Jimenez J, Rossi AM, Paus R, Lacouture ME.

J Am Acad Dermatol. 2018 Apr 13. pii: S0190-9622(18)30530-9. doi: 10.1016/j.jaad.2018.03.056. [Epub ahead of print] Review.

PMID:
29660423
7.

CME Part 1: Hair disorders in cancer patients.

Freites-Martinez A, Shapiro J, Goldfarb S, Nangia J, Jimenez JJ, Paus R, Lacouture ME.

J Am Acad Dermatol. 2018 Apr 13. pii: S0190-9622(18)30529-2. doi: 10.1016/j.jaad.2018.03.055. [Epub ahead of print] Review.

PMID:
29660422
8.

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME.

Oncologist. 2018 Aug;23(8):891-899. doi: 10.1634/theoncologist.2017-0582. Epub 2018 Apr 12. Review.

PMID:
29650685
9.

Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer.

Freites-Martinez A, Shapiro J, Chan D, Fornier M, Modi S, Gajria D, Dusza S, Goldfarb S, Lacouture ME.

JAMA Dermatol. 2018 Jun 1;154(6):670-675. doi: 10.1001/jamadermatol.2018.0454.

PMID:
29641806
10.

Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.

Lacouture ME, Anadkat M, Jatoi A, Garawin T, Bohac C, Mitchell E.

Clin Colorectal Cancer. 2018 Jun;17(2):85-96. doi: 10.1016/j.clcc.2017.12.004. Epub 2017 Dec 13. Review.

11.

Taking it in the chin: vitamin K1 for the prevention of acneiform rash.

Lacouture ME.

Ann Oncol. 2018 Apr 1;29(4):796-798. doi: 10.1093/annonc/mdy084. No abstract available.

PMID:
29566217
12.

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis.

Bhatia A, Ulaner G, Rampal R, Hyman DM, Abdel-Wahab O, Durham BH, Dogan A, Ozkaya N, Lacouture ME, Hajdenberg J, Ganzel C, Diamond EL.

Haematologica. 2018 Apr;103(4):e177-e180. doi: 10.3324/haematol.2017.185298. Epub 2018 Feb 22. No abstract available.

13.

The microbial flora of taxane therapy-associated nail disease in cancer patients.

Virgen CA, Belum VR, Kamboj M, Goldfarb SB, Blinder VS, Gucalp A, Lacouture ME.

J Am Acad Dermatol. 2018 Mar;78(3):607-609. doi: 10.1016/j.jaad.2017.08.038. No abstract available.

PMID:
29447679
14.

SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation.

White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Holmes JH 4th, Hung SI, Lacouture ME, Lehloenya RJ, Mallal S, Manolio TA, Micheletti RG, Mitchell CM, Mockenhaupt M, Ostrov DA, Pavlos R, Pirmohamed M, Pope E, Redwood A, Rosenbach M, Rosenblum MD, Roujeau JC, Saavedra AP, Saeed HN, Struewing JP, Sueki H, Sukasem C, Sung C, Trubiano JA, Weintraub J, Wheatley LM, Williams KB, Worley B, Chung WH, Shear NH, Phillips EJ.

J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):38-69. doi: 10.1016/j.jaip.2017.11.023. Review.

PMID:
29310768
15.

Inflammatory dermatoses, infections, and drug eruptions are the most common skin conditions in hospitalized cancer patients.

Phillips GS, Freites-Martinez A, Hsu M, Skripnik Lucas A, Barrios DM, Ciccolini K, Marchetti MA, Deng L, Myskowski PL, Lee EH, Markova A, Lacouture ME.

J Am Acad Dermatol. 2018 Jun;78(6):1102-1109. doi: 10.1016/j.jaad.2017.12.031. Epub 2017 Dec 19.

PMID:
29273489
16.

Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.

Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M.

Am J Clin Dermatol. 2018 Jun;19(3):363-375. doi: 10.1007/s40257-017-0337-2. Review.

PMID:
29260411
17.

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.

Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, Varghese AM, Lacouture ME, Ribas A, Patel SP, DeCrescenzo GA, Emery CM, Groover AL, Saha S, Varterasian M, Welsch DJ, Hyman DM, Li BT.

Cancer Discov. 2018 Feb;8(2):184-195. doi: 10.1158/2159-8290.CD-17-1119. Epub 2017 Dec 15.

PMID:
29247021
18.

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group.

J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z.

19.

A survey of patient and physician acceptance of skin toxicities from anti-epidermal growth factor receptor therapies.

Tischer B, Bilang M, Kraemer M, Ronga P, Lacouture ME.

Support Care Cancer. 2018 Apr;26(4):1169-1179. doi: 10.1007/s00520-017-3938-7. Epub 2017 Nov 7.

20.

Granuloma annulare associated with immune checkpoint inhibitors.

Wu J, Kwong BY, Martires KJ, Rieger KE, Chung WH, Iyer GV, Lacouture ME.

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e124-e126. doi: 10.1111/jdv.14617. Epub 2017 Oct 27. No abstract available.

PMID:
28983973
21.

Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials.

Shah VV, Wikramanayake TC, DelCanto GM, van den Hurk C, Wu S, Lacouture ME, Jimenez JJ.

J Eur Acad Dermatol Venereol. 2018 May;32(5):720-734. doi: 10.1111/jdv.14612. Epub 2017 Nov 24. Review.

PMID:
28976026
22.

Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Dai J, Belum VR, Wu S, Sibaud V, Lacouture ME.

J Am Acad Dermatol. 2017 Nov;77(5):902-910.e2. doi: 10.1016/j.jaad.2017.06.044. Epub 2017 Sep 14. Review.

23.

Olmutinib-induced palmoplantar keratoderma.

Chen KL, Cho YT, Yang CW, Sheen YS, Liang CW, Lacouture ME, Chu CY.

Br J Dermatol. 2018 Feb;178(2):e129-e131. doi: 10.1111/bjd.15935. Epub 2017 Dec 18. No abstract available.

PMID:
28869782
24.

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern.

Kaunitz GJ, Loss M, Rizvi H, Ravi S, Cuda JD, Bleich KB, Esandrio J, Sander I, Le DT, Diaz LA Jr, Brahmer JR, Drake CG, Hollmann TJ, Lacouture ME, Hellmann MD, Lipson EJ, Taube JM.

Am J Surg Pathol. 2017 Oct;41(10):1381-1389. doi: 10.1097/PAS.0000000000000900.

25.

A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.

Belum VR, Marchetti MA, Dusza SW, Cercek A, Kemeny NE, Lacouture ME.

J Am Acad Dermatol. 2017 Sep;77(3):577-579. doi: 10.1016/j.jaad.2017.03.039. No abstract available.

26.

Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis.

Zarnegar S, Durham BH, Khattar P, Shukla NN, Benayed R, Lacouture ME, Lavi E, Lyden DC, Diamond EL, Dunkel IJ, Abdel-Wahab O.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26699. Epub 2017 Jul 27.

PMID:
28748614
27.

Post-reconstruction dermatitis of the breast.

Rosen AC, Goh C, Lacouture ME, Mehrara BJ, Cordeiro PG, Myskowski PL.

J Plast Reconstr Aesthet Surg. 2017 Oct;70(10):1369-1376. doi: 10.1016/j.bjps.2017.05.012. Epub 2017 May 20.

28.

Eruptive Keratoacanthomas Associated With Pembrolizumab Therapy.

Freites-Martinez A, Kwong BY, Rieger KE, Coit DG, Colevas AD, Lacouture ME.

JAMA Dermatol. 2017 Jul 1;153(7):694-697. doi: 10.1001/jamadermatol.2017.0989.

29.

Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.

Sibaud V, Eid C, Belum VR, Combemale P, Barres B, Lamant L, Mourey L, Gomez-Roca C, Estilo CL, Motzer R, Vigarios E, Lacouture ME.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):e464-e469. doi: 10.1111/jdv.14284. Epub 2017 May 8. No abstract available.

30.

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

Kim DW, Garon EB, Jatoi A, Keefe DM, Lacouture ME, Sonis S, Gernhardt D, Wang T, Giri N, Doherty JP, Nadanaciva S, O'Connell J, Sbar E, Cho BC.

Lung Cancer. 2017 Apr;106:76-82. doi: 10.1016/j.lungcan.2017.01.021. Epub 2017 Feb 1.

31.

A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM.

Invest New Drugs. 2017 Dec;35(6):742-750. doi: 10.1007/s10637-017-0445-0. Epub 2017 Mar 9.

PMID:
28281183
32.

Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.

Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, Motzer RJ, Busam KJ, Lacouture ME.

Br J Dermatol. 2017 Jun;176(6):1649-1652. doi: 10.1111/bjd.15237. Epub 2017 Apr 24.

33.

Development of Papulopustular Rosacea during Nivolumab Therapy for Metastatic Cancer.

Bousquet E, Zarbo A, Tournier E, Chevreau C, Mazieres J, Lacouture ME, Sibaud V.

Acta Derm Venereol. 2017 Apr 6;97(4):539-540. doi: 10.2340/00015555-2566. No abstract available.

34.

A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.

McArthur HL, Diab A, Page DB, Yuan J, Solomon SB, Sacchini V, Comstock C, Durack JC, Maybody M, Sung J, Ginsberg A, Wong P, Barlas A, Dong Z, Zhao C, Blum B, Patil S, Neville D, Comen EA, Morris EA, Kotin A, Brogi E, Wen YH, Morrow M, Lacouture ME, Sharma P, Allison JP, Hudis CA, Wolchok JD, Norton L.

Clin Cancer Res. 2016 Dec 1;22(23):5729-5737. Epub 2016 Aug 26.

35.

reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial' by Ceccarelli et al.

Lacouture ME; authors of the publication “A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer”.

Ann Oncol. 2016 Nov;27(11):2138-2139. Epub 2016 Sep 23. No abstract available.

36.

Dermatological adverse events with taxane chemotherapy.

Sibaud V, Lebœuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, Montastruc M, Eche A, Vigarios E, Dalenc F, Lacouture ME.

Eur J Dermatol. 2016 Oct 1;26(5):427-443. Review.

37.

Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.

Tischer B, Huber R, Kraemer M, Lacouture ME.

Support Care Cancer. 2017 Feb;25(2):651-660. doi: 10.1007/s00520-016-3419-4. Epub 2016 Oct 7. Review.

38.

Stoma care products represent a common and previously underreported source of peristomal contact dermatitis.

Cressey BD, Belum VR, Scheinman P, Silvestri D, McEntee N, Livingston V, Lacouture ME, Zippin JH.

Contact Dermatitis. 2017 Jan;76(1):27-33. doi: 10.1111/cod.12678. Epub 2016 Aug 31.

39.

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.

Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R.

Oncologist. 2016 Oct;21(10):1218-1229. Epub 2016 Aug 10. Review.

40.

Increased Airport Scrutiny by the Transportation Security Administration of a Patient-Passenger Carrying Ammonium Lactate-Containing Moisturizer.

Zarbo A, Ouerfelli O, Klang M, Lacouture ME.

JAMA Dermatol. 2016 Sep 1;152(9):1054-5. doi: 10.1001/jamadermatol.2016.2665. No abstract available.

PMID:
27486908
41.

Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid Tumors.

Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P, Guenther S, Zhang J, Lacouture ME, Jatoi A.

Oncologist. 2016 Dec;21(12):1483-1491. Epub 2016 Jul 22. Review.

42.

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.

Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, Doherty JP, Giri N, Nadanaciva S, O'Connell J, Sbar E, Piperdi B, Garon EB.

Ann Oncol. 2016 Sep;27(9):1712-8. doi: 10.1093/annonc/mdw227. Epub 2016 Jun 10.

PMID:
27287210
43.

Mechanisms of skin aging induced by EGFR inhibitors.

Gerber PA, Buhren BA, Schrumpf H, Hevezi P, Bölke E, Sohn D, Jänicke RU, Belum VR, Robert C, Lacouture ME, Homey B.

Support Care Cancer. 2016 Oct;24(10):4241-8. doi: 10.1007/s00520-016-3254-7. Epub 2016 May 10.

44.

Cold thermal injury from cold caps used for the prevention of chemotherapy-induced alopecia.

Belum VR, de Barros Silva G, Laloni MT, Ciccolini K, Goldfarb SB, Norton L, Sklarin NT, Lacouture ME.

Breast Cancer Res Treat. 2016 Jun;157(2):395-400. doi: 10.1007/s10549-016-3799-7. Epub 2016 May 5.

45.

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD.

Ann Oncol. 2016 Jul;27(7):1362. doi: 10.1093/annonc/mdw141. Epub 2016 Apr 12. No abstract available.

46.

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.

Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, Motzer RJ, Wu S, Busam KJ, Wolchok JD, Lacouture ME.

Eur J Cancer. 2016 Jun;60:12-25. doi: 10.1016/j.ejca.2016.02.010. Epub 2016 Apr 1. Review.

47.

Management of Dermatologic Toxicities Associated With Targeted Therapy.

Lacouture ME.

J Adv Pract Oncol. 2016 Apr;7(3):331-334. Epub 2016 Apr 1. Review. No abstract available.

48.

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Naidoo J, Schindler K, Querfeld C, Busam K, Cunningham J, Page DB, Postow MA, Weinstein A, Lucas AS, Ciccolini KT, Quigley EA, Lesokhin AM, Paik PK, Chaft JE, Segal NH, D'Angelo SP, Dickson MA, Wolchok JD, Lacouture ME.

Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29.

49.

Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.

Drilon A, Eaton AA, Schindler K, Gounder MM, Spriggs DR, Harris P, Ivy SP, Iasonos A, Lacouture ME, Hyman DM.

Cancer. 2016 Apr 15;122(8):1228-37. doi: 10.1002/cncr.29918. Epub 2016 Feb 24.

50.

A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.

Iyengar NM, Fornier MN, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM, Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME, Chen MF, Patil S, Baselga J, Norton L, Hudis CA, Dang CT.

Clin Breast Cancer. 2016 Apr;16(2):87-94. doi: 10.1016/j.clbc.2015.09.009. Epub 2015 Sep 25.

Supplemental Content

Loading ...
Support Center